Purine Supplementation in Patients With AICA-Ribosiduria

Recruiting N/A Interventional Study
AICA-ribosiduria Due to ATIC Deficiency
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
3 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
10 (estimated)
Sponsor
Centre Hospitalier Universitaire de Saint Etienne · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Individual affected by AICA-ribosiduria due to ATIC deficiency Exclusion Criteria: \- Individual already on a purine-rich diet theoretical contraindication to a purine-rich diet
Contacts

Francis RAMOND, doctor of medicine

0477828798

Francis.Ramond@chu-st-etienne.fr

CONTACT

Béatrice DEYGAS, Project manager

beatrice.deygas@chu-st-etienne.fr

CONTACT